Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic. the COVID-19 pandemic breast cancer consortium
- PMID: 32333293
- PMCID: PMC7181102
- DOI: 10.1007/s10549-020-05644-z
Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic. the COVID-19 pandemic breast cancer consortium
Abstract
The COVID-19 pandemic presents clinicians a unique set of challenges in managing breast cancer (BC) patients. As hospital resources and staff become more limited during the COVID-19 pandemic, it becomes critically important to define which BC patients require more urgent care and which patients can wait for treatment until the pandemic is over. In this Special Communication, we use expert opinion of representatives from multiple cancer care organizations to categorize BC patients into priority levels (A, B, C) for urgency of care across all specialties. Additionally, we provide treatment recommendations for each of these patient scenarios. Priority A patients have conditions that are immediately life threatening or symptomatic requiring urgent treatment. Priority B patients have conditions that do not require immediate treatment but should start treatment before the pandemic is over. Priority C patients have conditions that can be safely deferred until the pandemic is over. The implementation of these recommendations for patient triage, which are based on the highest level available evidence, must be adapted to current availability of hospital resources and severity of the COVID-19 pandemic in each region of the country. Additionally, the risk of disease progression and worse outcomes for patients need to be weighed against the risk of patient and staff exposure to SARS CoV-2 (virus associated with the COVID-19 pandemic). Physicians should use these recommendations to prioritize care for their BC patients and adapt treatment recommendations to the local context at their hospital.
Comment in
-
Treatment options for patients with HR+/HER2- advanced breast cancer during the COVID-19 pandemic: dose reduction of ribociclib does not diminish efficacy.Breast Cancer Res Treat. 2020 Jul;182(1):243-244. doi: 10.1007/s10549-020-05674-7. Epub 2020 May 20. Breast Cancer Res Treat. 2020. PMID: 32436148 Free PMC article. No abstract available.
References
-
- Ueda M, Martins R, Hendrie PC, et al. Managing Cancer Care During the COVID-19 Pandemic Agility and Collaboration Toward a Common Goal. J Nat Comprehen Cancer Net. 2020;1:1–4. - PubMed
-
- Ontario Health. Pandemic Planning Clinical Guideline for Patients with Cancer. 2020. https://www.accc-cancer.org/docs/documents/cancer-program-fundamentals/o.... Accessed 23 March 2020.
-
- Armes JE, Egan AJ, Southey MC, et al. The histologic phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations: a population-based study. Cancer. 1998;83(11):2335–2345. - PubMed
-
- Monticciolo DL, Newell MS, Moy L, Niell B, Monsees B, Sickles EA. Breast Cancer Screening in Women at Higher-Than-Average Risk: Recommendations From the ACR. J Am College Radiol. 2018;15(3):408–414. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
